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Pathophysiology of
ANCA-associated vasculitis:
Are ANCA really pathogenic?
A note of caution
To the Editor: In their recent article, Heeringa and
Cohen Tervaert summarized the evidences for the widely
accepted conception, that antineutrophil-cytoplasmic au-
toauntibodies (ANCA), by activating neutrophils, are the
“major players” in the pathogenesis of small vessel vas-
culitis [1]. We feel a note of caution is appropriate.
First, there is no evidence for binding of ANCA to
polymorphonuclear neutrophils (PMN) (or monocytes)
in vivo: in patients with high ANCA titer, immunoglob-
ulin G (IgG) deposits cannot be detected on PMN, al-
though the target antigen, for example, PR3, could be
detected by use of a heterologous antibody (e.g., in the
histologic study described in [2], or the the ex vivo anal-
ysis of peripheral blood PMN described in [3]).
Second, to the best of our knowledge, the experiments
using ANCA for activation of PMN in vitro were per-
fomed with purified IgG, or with heterologous antibod-
ies, respectively. According to our experience, the affinity
of the ANCA for PMN is far too low for binding in the
presence of other plasma proteins. With purified IgG, the
low affinity binding can be overcome by high input of pu-
rified protein. Thus, stimulation of PMN by ANCA may
not occur under in vivo conditions.
Third, in the studies with experimental animals (as
reported, e.g., in [4]), the antibodies generated against
myeloperoxidase (MPO) are not true autoantibodies, be-
cause animals deficient for MPO were used for immu-
nization. These animals are not tolerant to MPO, and
consequently, lymphocytes with high reactivity towards
“self-MPO” will not be eliminated, leading to the gener-
ation of antibodies with high affinity binding. In contrast,
when self-tolerance is operative (as it is in humans), anti-
bodies with low affinity binding are produced, which will
greatly differ with regard to their interaction with poten-
tial target antigens.
While these argument do not necessarily rule out a role
of ANCA in vasculitis—or of the PMN—they challenge
the current model of ANCA-mediated PMN activation
as a major pathogenic factor.
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Reply from the Authors
We would like to respond to the issues raised con-
cerning our recent paper on the pathogenic potential of
ANCA [1]. First, it is stated that there is no evidence for
binding of ANCA to PMN in vivo. In our view, such stud-
ies would be technically very challenging, and multiple
reasons can be given for a negative outcome of such stud-
ies. Among others, these include the rapid clearing from
the circulation of ANCA-coated PMNs and the possibil-
ity of internalization of the membrane-bound MPO/anti-
MPO or Pr3/anti-Pr3 immune complexes.
The second issue concerns the affinity of ANCA for
their target antigens on the PMN surface being too low
to induce PMN activation in vivo. Although studies have
been performed using ANCA containing whole sera [2],
purification of the autoantibodies is common practice to
avoid confounding PMN activating mediators (e.g., cy-
tokines) that could be present in whole sera. Although it is
difficult to directly translate the results from such in vitro
studies to the in vivo situation in patients, they clearly
indicate that ANCA, under the right circumstances, can
activate PMN. In our view, this probably does not occur
systemically but locally when PMNs have bound to en-
dothelial cells. Other factors (infection?) are needed ini-
tially to create a proinflammatory environment, resulting
in PMN priming and adherence to activated endothelium.
